Indeed, targeting the NF-κB pathway is an important therapeutic strategy for RA, and inhibiting NF-κB (with anti-tumor necrosis factor(TNF) drugs) has shown good safety and efficacy in the treatment of this disease [4, 5]. Here, NFKB1 is linked to rheumatoid arthritis.